We discovered that S100A16 may influence the biological processes of RCC by engaging in the VEGF/VEGFR2 signaling pathway, P53 alterations, cell cycle, and PI3K-Akt signaling pathway, therefore altering the prognosis of RCC. Here, VEGFA is linked to renal cell adenocarcinoma.